Samsung Bioepis, J&J Ink Settlement and License Deal for Stelara Biosimilar

Samsung Bioepis has inked a settlement and license agreement with Johnson & Johnson, which will settle all U.S. patent litigation and allow for the commercialization of a biosimilar for the arthritis drug Stelara, known as SB17.